

Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)

NCT07240558

| | |
|-------------------|------------------------------------|
| Status | RECRUITING |
| Phase | Phase 3 |
| Sponsor | University Health Network, Toronto |
| Enrollment | 120 participants |

Key Eligibility Criteria

Inclusion (4)

- Age ≥ 18 and greater than 3 months post-transplant
- Stable graft function
- eGFR \geq 30 mL/min/1.73 m²
- Able to provide informed consent

Exclusion (13)

- Allergy to vaccine components;
- Previous life-threatening reaction to influenza vaccine (ie Guillain Barré Syndrome);
- Ongoing or recent therapy for acute rejection (within the previous 30 days);
- Ongoing active cytomegalovirus (CMV) infection with viral load of greater or equal to 1000 international units/ml in the last 7 days;
- Febrile illness in the past 2 weeks;
- ... and 8 more (see full listing online)

Locations (1 total)

University Health Network, Toronto, Ontario, Canada